FDA Stands Firm: Clinical Trials Exploring Structure/Function Effects Need IND
This article was originally published in The Rose Sheet
Executive Summary
Despite industry's assertion that FDA is unlawfully reinterpreting statutory definitions under the Federal Food, Drug and Cosmetic Act, the agency's republished final guidance maintains that cosmetics evaluated for structure/function effects in clinical trials require Investigational New Drug go-ahead before being transported from one state to another. Anti-aging skin- and hair-care research could be impacted most.
You may also be interested in...
Dietary Ingredient Studies For Health Benefits Could Be Fenced In By US FDA IND Proposal
Proposed rule introduces two exemptions agency would allow from needing IND clearance for clinical investigations to evaluate food, supplements or cosmetics. Both begin with basic requirement of trial not intended to support drug development plan or labeling change that would make a food, dietary ingredient or cosmetic an unlawfully marketed drug.
FDA Rulemaking Could Be Imminent On Investigational New Drug Requirements For Cosmetics, Dietary Supplements
Are investigational new drug applications required for clinical trials conducted by cosmetics companies to evaluate potential body structure/function effects, or clinical studies undertaken by dietary supplement companies to support a new or expanded health claim? FDA said they are in final guidance reissued in late 2015 and now has rulemaking planned on the subject that could commence this month.
FDA Warns Former AAD President For DNA Eye Renewal Claims
Ronald Moy, a cosmetic surgeon practicing in Los Angeles and former president of the American Academy of Dermatology, receives an FDA warning letter for unapproved drug claims on his DNA Eye Renewal product, part of the doctor’s DNAEGF Renewal line marketed online. The warning, newly posted to FDA’s website, was one of three that went out to cosmetics players Feb. 12.